Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Cash Flows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net (loss) income	$ (293,623,000)	$ 66,048,000	$ 43,793,000
Changes in assets and liabilities:
Net cash provided by operating activities	131,341,000	83,286,000	45,253,000
Cash flows from investing activities
Distribution from subsidiary	0	0	606,000,000
Net cash used in investing activities	(91,617,000)	(37,055,000)	(3,458,000)
Cash flows from financing activities
Issuance of preferred stock, net			737,009,000
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	891,793,000
Proceeds from private placement with a related party	100,000,000
Payments of initial public offering issuance costs	(4,937,000)
Issuance of common stock		1,623,000
Dividends paid			(1,346,355,000)
Proceeds from exercise of stock options	5,343,000	3,042,000	3,349,000
Proceeds from early exercise of stock options	667,000
Employee taxes paid related to net share settlement of equity awards	(78,714,000)
Net cash provided by (used in) financing activities	905,817,000	(54,781,000)	(24,734,000)
Net change in cash, cash equivalents and restricted cash	945,541,000	(8,550,000)	17,061,000
Cash
Beginning of year	26,050,000	34,600,000	17,539,000
End of year	971,591,000	26,050,000	34,600,000
GoodRx Holdings, Inc
Cash flows from operating activities
Net (loss) income	(293,623,000)	66,048,000	43,793,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Equity in loss (earnings) of subsidiary	293,623,000	(66,048,000)	(43,793,000)
Changes in assets and liabilities:
Other asset	90,000	(147,000)
Other current liabilities	87,000
Net cash provided by operating activities	177,000	(147,000)
Cash flows from investing activities
Distribution from subsidiary			605,997,000
Investment in subsidiary	(914,434,000)	(4,908,000)
Net cash used in investing activities	(914,434,000)	(4,908,000)	605,997,000
Cash flows from financing activities
Issuance of preferred stock, net			737,009,000
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	891,793,000
Proceeds from private placement with a related party	100,000,000
Payments of initial public offering issuance costs	(4,937,000)
Issuance of common stock		1,623,000
Dividends paid			(1,346,355,000)
Proceeds from exercise of stock options	5,343,000	3,042,000	3,349,000
Proceeds from early exercise of stock options	667,000
Employee taxes paid related to net share settlement of equity awards	(78,714,000)
Net cash provided by (used in) financing activities	914,152,000	4,665,000	(605,997,000)
Net change in cash, cash equivalents and restricted cash	(105,000)	(390,000)
Cash
Beginning of year	110,000	500,000	500,000
End of year	$ 5,000	$ 110,000	$ 500,000